-

Kaskela Law LLC Announces Shareholder Investigation of Redwire Corporation (NYSE: RDW) and Encourages Long-Term RDW Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Redwire Corporation (NYSE: RDW) (“Redwire”), formerly known as Genesis Park Acquisition Corp., on behalf of the company’s long-term shareholders.

https://kaskelalaw.com/case/redwire-corporation/

Recently a securities fraud complaint was filed against Redwire on behalf of investors who purchased shares of the company’s stock between March 25, 2021 and March 31, 2022. According to the complaint, during that time period Redwire and certain of the company’s senior executive officers “omitted to disclose material deficiencies in Redwire’s internal controls over its financial disclosures – a fact Redwire’s senior management knew, but desperately tried to conceal, including through touting their “dedicate[ion] to conducting business with efficiency, fairness and integrity and encourage[ing] behavior that will maintain the public’s confidence and trust in [Redwire’s] operations.”

The complaint further details how, through a series of partial disclosures beginning in November 2021, investors slowly learned the truth about the company’s prior misrepresentations and suffered economic damages as a result therefrom. For example, on November 10, 2021, just over two months after going public, Redwire announced that it would postpone releasing its quarterly earnings results and that it was investigating internal allegations of accounting issues. Following this news, shares of Redwire’s stock fell $1.92 per share, or over 16% in value, to close on November 10, 2021 at $9.99 per share. Five days later, on November 15, 2021, Redwire gave an update saying that it could not timely file its quarterly report, sending the stock down another 8% in value.

Subsequently, on March 31, 2022, Redwire released its internal audit results, which indicated a host of internal procedural and control failures, including “an additional material weakness” beyond the company’s “previously identified internal control deficiencies.” Following this additional news, shares of Redwire’s stock fell an additional $2.43 per share, or over 28% in value, to close on April 1, 2022 at $6.05 per share, on heavy trading volume.

The investigation seeks to determine whether the members of Redwire’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct and disclosures.

Current Redwire shareholders who purchased or acquired shares of RDW stock prior to March 31, 2022 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750 for additional information about this investigation and their legal rights and options. Alternatively, investors may submit their information to the firm by clicking on the following link (or by copying and pasting the link into your browser):

https://kaskelalaw.com/case/redwire-corporation/

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

This notice may constitute attorney advertising in certain jurisdictions.

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

Kaskela Law LLC

NYSE:RDW

Release Versions

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

More News From Kaskela Law LLC

Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company’s current shareholders. The investigation seeks to determine whether Amneal or the company’s officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions. Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional infor...

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th...

Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Fortrea Holdings Inc. (Nasdaq: FTRE) (“Fortrea”) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/fortrea-holdings/ Recently a securities fraud complaint was filed against Fortrea on behalf of certain investors who purchased shares of the company’s stock between July 5, 2023 and February 28, 2025 (the “Wrongdoing Period”). Accor...
Back to Newsroom